Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material.
Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992.
For patients, we provide the latest patient information leaflets and training materials as well as the technical information for Berlin-Chemie products available in Germany via our Medical Hub.
Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.
Discover More about Global Responsibility
From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet
Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice.
Discover More about Global Partnering
Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.
Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.
Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.
Menarini Blog
Follow Us
We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.
Our Job Portal
Find out about our current vacancies at Berlin-Chemie directly on our career portal.
2018 - 06 - 01
Menarini Ricerche to present the Study design of CD205-Shuttle, a first-in-human trial of MEN1309/OBT076, at the ASCO Annual Meeting 2018
Pomezia, Italy, June 1, 2018 - Menarini Ricerche (Menarini Group) will present at ASCO Annual Meeting 2018 the study design of CD205-Shuttle, a multicenter first-in-human clinical study to evaluate MEN1309/OBT076, an antibody drug conjugate (ADC) investigated for the treatment of metastatic solid tumors and non-Hodgkin’s lymphoma (NHL).
MEN1309/OBT076 is a fully humanized IgG1 monoclonal antibody, in co-development with Oxford BioTherapeutics (OBT), conjugated to a potent cytotoxic maytansinoid toxin via a cleavable linker. The ADC is directed against a type I transmembrane glycoprotein CD205/Ly75, that is over-expressed in several solid tumors and NHL.
The poster “CD205-Shuttle study: A first-in-human trial of MEN1309/OBT076 an ADC targeting CD205 in solid tumor and NHL” focused on the innovative design of the dose-escalation study will be presented during the session “Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics” Abstract no. TPS2606, on June 4, 2018 between 8:00 AM-11:30 AM at the McCormick Place Convention Center in Chicago, Illinois.
The CD205-Shuttle study is ongoing in major European oncology centers in Italy, Spain, Belgium and the UK. The study investigated to date 5 dose levels. The sixth dose level is currently being evaluated.